|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:tenofovir_disoproxil_fumarate
gptkb:Zidovudine
gptkb:Cabenuva
gptkb:Juluca
gptkb:Vocabria
gptkb:emtricitabine
|
|
gptkbp:activities
|
non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Edurant
|
|
gptkbp:can_be_used_with
|
gptkb:tenofovir
gptkb:emtricitabine
|
|
gptkbp:clinical_trial
|
HIV-1 infection
first-line therapy
treatment-experienced patients
NC T01350732
NC T01350746
NC T01350759
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to rilpivirine
|
|
gptkbp:developed_by
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:dosage_form
|
once daily
|
|
gptkbp:formulation
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rilpivirine
|
|
gptkbp:ingredients
|
C22 H22 N6 O2
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:rifampin
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_atype_of
|
J05 A E09
|
|
gptkbp:is_used_for
|
treatment of HIV
|
|
gptkbp:lifespan
|
45 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Edurant
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
metabolized by CY P3 A4
|
|
gptkbp:research_focus
|
long-acting formulations
HIV treatment regimens
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
gptkb:historical_event
headache
nausea
rash
insomnia
|
|
gptkbp:storage
|
room temperature
protected from moisture
|
|
gptkbp:type_of
|
150107-68-0
|